Increasing evidence has illustrated that inhibiting the formation of 4-OH-E2 by binding to a CYP1B1 activity site or the CYP1B1-catalyzed enzymes (Meng et al., 2019) might be a pivotal mechanism of AG in alleviating breast cancer. This evidence concerns the gene CYP1B1 and breast cancer.